Mazdutide (IBI362) is a synthetic peptide functioning as a dual GLP-1 receptor and glucagon receptor (GcgR) agonist. Its design seeks to combine the insulin-sensitizing and appetite-regulatory effects of GLP-1 receptor activation with the thermogenic and hepatic fat-mobilizing properties attributed to glucagon receptor engagement. This dual mechanism distinguishes it from selective GLP-1R agonists such as semaglutide and from triple agonists such as retatrutide.
GLP-1 Receptor Agonism Research
Research has examined mazdutide's engagement of the GLP-1 receptor and its downstream effects on glucose-stimulated insulin secretion, gastric emptying regulation, and central appetite signaling in experimental models.
Glucagon Receptor Agonism and Energy Expenditure Research
Preclinical and clinical research has explored the contribution of mazdutide's glucagon receptor component to resting energy expenditure and hepatic lipid metabolism. Glucagon receptor engagement is thought to influence thermogenesis, hepatic fat oxidation, and mitochondrial biogenesis.
Clinical Research Profile
Mazdutide has been evaluated in Phase 2 and Phase 3 clinical trials primarily conducted in China. Results have been presented at major endocrinology conferences and published in peer-reviewed journals.
• Xiao X et al. (2023). Efficacy and safety of mazdutide in Chinese adults with overweight or obesity: a Phase 2 randomised trial. The Lancet Diabetes & Endocrinology, 11(7), 498–508.
